a phase II trial of amrubicin and carboplatin for patients with extensive stage small cell lung cancer

a phase II trial of amrubicin and carboplatin for patients with extensive stage small cell lung cancer - PII of AMR/CBDCA for EDSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001115

Enrollment

Registered

2008-04-09

Start date

2008-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

amurubicin+carboplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histological confiremd small cell lung cancer 2. extensive stage 3. chemotherapy naive 4. expectable 12 week survival 5. have measurable lesion 6. 75 years or younger 7. performance status 0, 1, 2 for Eastern Cooperative Oncology Group (ECOG) 8. adequate organ function 9. written informed consent

Exclusion criteria

Exclusion criteria: 1. severe cardiac effusion 2. severe supra vena cava syndrome 3. severe complication (angina pectoris, myocardial infarction, heart failure, diabetes, hypertension, infection, interstitial pneumonia) 4. active other cancer 5. pregnancy women 6. need radiotherapy for brain metastasis 7. limited stage small cell lung cancer

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
progression free survival, overall survival, toxicity	—

Countries

Japan

Contacts

Public ContactMinoru Fukuda

Nagasaki Municipal Hospital Internal Medicine

mifukuda258@nifty.com090-822-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026